<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26440">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762539</url>
  </required_header>
  <id_info>
    <org_study_id>Omega 3 head injury</org_study_id>
    <nct_id>NCT02762539</nct_id>
  </id_info>
  <brief_title>Omega3 PUFA in Head Trauam</brief_title>
  <acronym>SMOFbrain</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traumatic brain injury (TBI) is major health problem that stands as a significant cause of
      death and permanent disability. TBI is considered as global public health epidemic. On
      pathophysiologic basis, TBI is described as occurring in two phases, primary and secondary.
      Once a primary insult occurs like trauma or ischemia, the secondary injury begins though
      main four mechanisms; ischemia, brain edema, axonal injury and neuro-inflammation. Omega-3
      PUFAs (Polyunsaturated fatty acids) are postulated to have neuroregenerative properties with
      the ability to impact all four main mechanisms of the secondary injury Patients will be
      allocated into one of two groups through a random table generation; Control group in which
      patients will follow our local protocol for TBI management without SMOF-lipid infusion.
      SMOF-lipid group in which patients will receive 0.5 g/Kg SMOF lipid 10% emulsion (Lipid
      emulsion for intravenous nutrition containing; 6% soybean oil / 6% medium chain
      triglycerides / 5% olive oil / 3%fish oil) daily over 12 hours starting once admitted to ICU
      for 7 days
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glasgow coma scale after 48 hour of infusion</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group in which patients will follow our local protocol for TBI management without SMOF-lipid infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMOF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMOF-lipid group in which patients will receive 0.5 g/Kg SMOF lipid 10% emulsion (Lipid emulsion for intravenous nutrition containing; 6% soybean oil / 6% medium chain triglycerides / 5% olive oil / 3%fish oil) daily over 12 hours starting once admitted to ICU for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 enriched SMOF lipid emusion</intervention_name>
    <arm_group_label>SMOF group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild to moderate head trauma

        Exclusion Criteria:

          -  sensitivity to SMOF lipid severe head trauama
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 5, 2016</lastchanged_date>
  <firstreceived_date>May 3, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>AlRefaey Kandeel</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
